Lumenis is Proud to Support the First International Scar Treatment Conference in Israel - Seite 2

International Scar Treatment Conference attendees are invited to attend sessions and workshops featuring a variety of Lumenis systems for skin and scar treatments including UltraPulse®, the most powerful CO2 laser in aesthetic medicine, AcuPulse(TM), a MultiMode(TM) SuperPulse(TM) CO2 Laser and M22(TM), a modular multi-application system for the treatment of over 30 skin conditions.  The full agenda can be found here.
 
"Our treatment, utilizing the unique UltraPulse technology, yields truly remarkable results for burn scars," said Tzipi Ozer-Armon, CEO of Lumenis. "As a company, we are honored to lead and advance medical solutions of this nature to benefit veterans around the world and the population at large. Lumenis is proud to support the first International Scar Treatment Conference in Israel, and looks forward to continuing to support these incredible doctors and their efforts."

For more information about the Lumenis family of fractional ablative laser resurfacing products and its portfolio of innovative scar treatment solutions, please visit Lumenis booth # 6-7 at the conference, presented in cooperation with Alphamedix, the Lumenis distributor in Israel.

About Lumenis
Lumenis is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology, and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For 50 years, Lumenis' ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods. For more information visit: www.lumenis.com 

Forward-Looking Statements
Information provided in this press release may contain statements relating to current expectations, estimates, forecasts and projections about future events that are forward-looking statements. These forward-looking statements may include but are not limited to the Company's plans, objectives and expectations for future operations, including its projected results of operations. Forward-looking statements are often characterized by the use of forward-looking terminology such as "may," "will," "expect," "anticipate," "estimate," "continue," "believe," "should," "intend," "plan," "project" or other similar words, but are not the only way these statements are identified. These forward-looking statements are based upon our management's current estimates and projections of future results or trends. Actual results may differ materially from those projected as a result of certain risks and uncertainties. These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether a result of new information, future events or otherwise.

For further information, contact:
Taylor Palkovich
5W Public Relations
Tel: [phone]
Email: [e-mail]

---

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Lumenis Ltd. via Globenewswire